Wockhardt Shares Climb 14% after Getting Approval for Two New Antibiotics
In a filing to stock exchanges, Wockhardt said that it has received approval from the Drugs Controller General of India (DCGI) for its two new antibiotics -- Emrok (intravenous infusion) and EMROK O (Oral) – to treat skin and other drug-resistant infections.